Evidence map›Paper›PMID 39766091›Full record

ReviewCancers2024

Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications.

Luca Guarnera, Emiliano Fabiani, Giulia Falconi, Giorgia Silvestrini, Maria Luigia Catanoso, Mariadomenica Divona, Maria Teresa Voso

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luca GuarneraPhD in Immunology, Molecular Medicine and Applied Biotechnology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-8293-0663
Emiliano FabianiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Giulia FalconiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7699-1427
Giorgia SilvestriniPhD in Immunology, Molecular Medicine and Applied Biotechnology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0009-0001-0665-6241
Maria Luigia CatanosoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Mariadomenica DivonaPoliclinico Universitario Tor Vergata, 00133 Rome, Italy.
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6164-4761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is a rare type of AML, characterized by the t(15;17) translocation and accounting for 8-15% of cases. The introduction of target therapies, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), radically changed the management of APL, making it the most curable AML subtype. However, a small percentage (estimated to be 2%) of AML presenting with APL-like morphology and/or immunophenotype lacks t(15;17). This rare APL-like AML group, whose first case was described in the early 1990s, now includes over 40 entities. These diseases present great heterogeneity in terms of genetic lesions, clinical presentation, sensitivity to targeted agents and chemotherapy, and prognosis. Furthermore, the diagnosis is very challenging. Thus, in this paper, we aim to comprehensively review the literature reports and studies addressing APL-like entities, investigate the biological mechanisms of leukemogenesis, evaluate the clinical characteristics, and discuss future lines of research and possible clinical approaches.

Indexed as

acute promyelocytic leukemiaAPLAPL-like AMLsatypical rearrangementsPLZF::RARARARARARBRARG

Identifiers

PMID39766091
PMCPMC11674562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.